Sanofi - ADR (SNY): Price and Financial Metrics


Sanofi - ADR (SNY)

Today's Latest Price: $50.14 USD

0.13 (-0.26%)

Updated Oct 19 9:50pm

Add SNY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SNY Stock Summary

  • Sanofi's market capitalization of $126,059,729,380 is ahead of 98.49% of US-listed equities.
  • With a year-over-year growth in debt of 54.84%, Sanofi's debt growth rate surpasses 81.14% of about US stocks.
  • In terms of volatility of its share price, SNY is more volatile than just 1.17% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Sanofi, a group of peers worth examining would be BMY, AZN, AMGN, IBM, and MDT.
  • Visit SNY's SEC page to see the company's official filings. To visit the company's web site, go to www.sanofi.com.

SNY Stock Price Chart Interactive Chart >

Price chart for SNY

SNY Price/Volume Stats

Current price $50.14 52-week high $55.00
Prev. close $50.27 52-week low $37.62
Day low $50.04 Volume 787,900
Day high $51.01 Avg. volume 1,737,842
50-day MA $50.88 Dividend yield 2.33%
200-day MA $49.39 Market Cap 125.56B

Sanofi - ADR (SNY) Company Bio


Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. The company was founded in 1973 and is based in Paris, France.

SNY Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$50.14$61.43 22%

We started the process of determining a valid price forecast for Sanofi with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Sanofi ranked in the 51th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 22.83% on a DCF basis. The most interesting components of our discounted cash flow analysis for Sanofi ended up being:

  • In the past 4.99 years, Sanofi has a compound free cash flow growth rate of 0.02%; that's higher than merely 21.74% of free cash flow generating stocks in the Healthcare sector.
  • Sanofi's weighted average cost of capital (WACC) is 7%; for context, that number is higher than only 8.41% of tickers in our DCF set.
  • SNY's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than only 8.41% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%20%
1%21%
2%22%
3%23%
4%25%
5%26%

DYNT, HRC, LH, CBPO, and ENSG can be thought of as valuation peers to SNY, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


SNY Latest News Stream


Event/Time News Detail
Loading, please wait...

SNY Latest Social Stream


Loading social stream, please wait...

View Full SNY Social Stream

Latest SNY News From Around the Web

Below are the latest news stories about Sanofi that investors may wish to consider to help them evaluate SNY as an investment opportunity.

Sanofi application for enzyme replacement therapy for rare sugar metabolism disorder accepted in Europe

The European Medicines Agency ((EMA)) accepts for review Sanofi's (SNY) marketing application seeking approval of enzyme replacement therapy avalglucosidase alfa for the treatment of Pompe disease, a rare inherited disorder characterized by the buildup of a sugar called glycogen in the body's cells due to the absence of key enzyme...

Seeking Alpha | October 2, 2020

EMA accepts Sanofi's marketing application for avalglucosidase for Pompe disease

The European Medicines Agency ((EMA)) has accepted for review Sanofi's (SNY) marketing authorization application for avalglucosidase alfa, for long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid α-glucosidase deficiency). Pompe disease is a rare, degenerative muscle disorder that can impact an individual’s ability to move and...

Seeking Alpha | October 2, 2020

Insulin API Market Prescribes Strong Growth, Business Enhancing Strategies, CAGR Status, by Forecast 2025| Sanofi, Novo Nordisk

The research study covers the current scenario and growth prospects of the Insulin API market (2020-2025) according to the analysis . This study includes a extensive analysis of the key segments of the industry and also the regional analysis

OpenPR | October 2, 2020

Insulin Market is Forecast To Reach USD 35.74 Billion By 2027 | Sanofi, Eli Lily and Company, ADOCIA, Julphar, Pfizer, Inc

The latest updated report on the Global Insulin Market added by Reports and Data presents a comprehensive analysis of the industry size, revenue forecast, regional spectrum of the business vertical, and further elaborates on the major hurdles, challenges, and latest

OpenPR | October 2, 2020

Global $6 Billion Diabetes Reusable Insulin Delivery Pen Market to 2026 with Sanofi, Ypsomed, Biocon, Novo Nordisk, Eli Lilly and Co, Owen Mumford & Berlin-Chemie Dominating

DUBLIN , Oct. 2, 2020 /PRNewswire/ -- The "Worldwide Diabetes Reusable Insulin Delivery Pen Market: Demand, Insights, Trends, Analysis, Opportunities, Growth Potential and Forecast to 2026" report has been added to ResearchAndMarkets.com's offering. The Worldwide Diabetes Reusable Insulin Delivery Pen Market size is expected to touch US$ 6 billion by 2026. The report offers the most up-to-date industry data on the actual market situation and future outlook for the worldwide diabetes reusable insulin delivery pen market. The report provides historical market data for 2013 - 2019, and forecasts from 2020 until 2026. The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, reusable insulin pen volume, revenues for reusable...

Benzinga | October 2, 2020

Read More 'SNY' Stories Here

SNY Price Returns

1-mo -4.39%
3-mo -5.79%
6-mo 6.60%
1-year 11.26%
3-year 14.58%
5-year 21.34%
YTD 2.33%
2019 23.73%
2018 4.20%
2017 8.73%
2016 -2.52%
2015 -3.37%

SNY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full SNY Dividend History

Continue Researching SNY

Want to see what other sources are saying about Sanofi's financials and stock price? Try the links below:

Sanofi (SNY) Stock Price | Nasdaq
Sanofi (SNY) Stock Quote, History and News - Yahoo Finance
Sanofi (SNY) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8089 seconds.